Cordlife Group Limited
AboutCordlife Group Limited is listed on the Mainboard of the Singapore Exchange (SGX), and together with its subsidiaries, may be called "The Group". Cordlife Group Limited owns five cord blood banks in Singapore, Hong Kong, Indonesia, Philippines and India, and has a direct investment in China Cord Blood Corporation, one of the top banks in China. Cordlife also currently owns over 30% of Stemlife Malaysia. At present the laboratories in Singapore, Hong Kong, and India are accredited by AABB (formerly known as American Association of Blood Banks), meeting the gold standard of private cord blood banking. The Group now comprises of:
Cordlife Group Limited - Singapore
Cordlife (Hong Kong) Limited - Hong Kong & Macau
Cordlife Sciences India Pvt Limited - Kolkata, India
PT Cordlife Persada - Jakarta, Indonesia
Cordlife Medical Philippines, Inc. - Manila, Philippines
Cordlife Group Limited was established in Singapore in 2001 to provide a full suite of cord blood and (subsequently) tissue banking services which include the collection, processing and cryopreservation of cord blood stem cells and umbilical cord tissue. Cordlife has grown rapidly from a fledging start-up company into a multi-national corporation. In 2005, Cordlife established its first overseas cord blood processing and storage facility in Hong Kong. The ISO certified facility, with a storage capacity for 50,000 cord blood and umbilical cord units, is Hong Kong’s largest and most advanced stem cell facility. In 2011, Cordlife introduced the patented technology, CellOptima™, which is exclusively available at Cordlife in Hong Kong, to isolate two types of stem cells from umbilical cord – Epithelial stem cells and Mesenchymal Stem Cells (MSC).